Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 28:12:1756286419838096.
doi: 10.1177/1756286419838096. eCollection 2019.

An update on best practice of deep brain stimulation in Parkinson's disease

Christian J Hartmann  1 , Sabine Fliegen  2 , Stefan J Groiss  2 , Lars Wojtecki  2 , Alfons Schnitzler  2
Affiliations
Review

An update on best practice of deep brain stimulation in Parkinson's disease

Christian J Hartmann et al. Ther Adv Neurol Disord. .

Abstract

During the last 30 years, deep brain stimulation (DBS) has evolved into the clinical standard of care as a highly effective treatment for advanced Parkinson's disease. Careful patient selection, an individualized anatomical target localization and meticulous evaluation of stimulation parameters for chronic DBS are crucial requirements to achieve optimal results. Current hardware-related advances allow for a more focused, individualized stimulation and hence may help to achieve optimal clinical results. However, current advances also increase the degrees of freedom for DBS programming and therefore challenge the skills of healthcare providers. This review gives an overview of the clinical effects of DBS, the criteria for patient, target, and device selection, and finally, offers strategies for a structured programming approach.

Keywords: Deep Brain Stimulation; Parkinson’s Disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: CJH received a travel grant from Abbott; SF declares no conflicts of interest; SJG received honoraria and travel expenses from Medtronic, Abbott, and Boston Scientific; LW received honoraria from Medtronic and Abbott/St. Jude Medical; AS received honoraria from Abbott, Boston Scientific, Medtronic and Abbvie.

References

    1. Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med 1998; 339: 1044–1053. - PubMed
    1. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 2009; 8: 1150–1157. - PubMed
    1. Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med 2011; 1: a008862. - PMC - PubMed
    1. Birkmayer W, Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 1961; 73: 787–788. - PubMed
    1. Benabid AL, Pollak P, Louveau A, et al. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987; 50: 344–346. - PubMed